Video Experimental Relacionado

Updated: Jan 8, 2026

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

Aceptabilidad del tratamiento preventivo de la tuberculosis multirresistente: una encuesta retrospectiva

Emily Lai-Ho MacLean^1,2, Yen Ngoc Pham³, Cuong Duc Pham³

¹NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

ERJ open research

|December 24, 2025

Resumen

Este estudio encuestó las experiencias de los pacientes con un tratamiento preventivo de levofloxacina de 6 meses para la tuberculosis multirresistente. Si bien en general fue aceptable, la mayoría de los pacientes indicaron que no repetirían el régimen.

Área de la Ciencia:

Enfermedades Infecciosas
Salud Pública
Farmacología

Sus antecedentes:

La tuberculosis multirresistente (TB-MDR) representa un desafío significativo para la salud mundial.
Los regímenes de tratamiento preventivo son cruciales para controlar la transmisión de la TB-MDR.
La levofloxacina es un antibiótico clave utilizado en el tratamiento y la prevención de la TB-MDR.

Objetivo del estudio:

Evaluar las experiencias y la aceptabilidad de los pacientes de un régimen de tratamiento preventivo de levofloxacina de 6 meses para la TB-MDR.
Identificar los factores que influyen en la adherencia del paciente y la voluntad de repetir el tratamiento.

Principales métodos:

Encuesta retrospectiva de pacientes que completaron un régimen de tratamiento preventivo de levofloxacina de 6 meses.
Recopilación de datos sobre experiencias reportadas por los pacientes, efectos secundarios y aceptabilidad general.
Análisis de las respuestas para determinar la satisfacción y la probabilidad de retratamiento.

Principales resultados:

El régimen de levofloxacina de 6 meses fue ampliamente aceptable para los pacientes.
Sin embargo, la mayoría de los encuestados expresaron su falta de voluntad para tomar el régimen nuevamente.
Las razones comunes de la falta de voluntad pueden estar relacionadas con efectos secundarios o duración, lo que requiere una mayor investigación.

Conclusiones:

Si bien la terapia preventiva con levofloxacina es factible, la voluntad del paciente de repetir el tratamiento es una preocupación.
Se necesitan estrategias para mejorar la experiencia del paciente y la adherencia a largo plazo.
La investigación adicional debe explorar regímenes alternativos o medidas de apoyo para mejorar la aceptabilidad del tratamiento preventivo de la TB-MDR.

Palabras clave:

tratamiento preventivo tuberculosis multirresistente levofloxacina aceptabilidad experiencia del paciente disposición a la retratamiento

Más Videos Relacionados

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Videos de Conceptos Relacionados

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...